Potter Clarkson are proud to announce that a number of our partners have been nominated by their peers as some of the world's leading practitioners in the 2019 "Who's Who Legal" series.
In the on-going case of Abraxis v Comptroller General of Patents, Advocate General Saugmandsgaard Øe proffered his non-binding opinion at the Court of Justice of the European Union concerning Supplementary Protection Certificates for new formulations of medicinal products.
Aspiring biotech businesses looking to gain a foothold in the fledgling European medical cannabis industry should take a leaf from their Canadian counterparts on intellectual property, say specialist life sciences patent attorneys Micheline Gravelle and Jane Wainwright.
Potter Clarkson is delighted to announce that it has secured a global settlement for its client Alnylam Pharmaceuticals, Inc., the world’s leading RNAi therapeutics company, of worldwide litigation with Silence Therapeutics PLC.
Potter Clarkson is delighted to announce the relocation of its Stockholm office to new and larger premises.
In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan explores the lessons for patent drafting.